FindTrial
Sign In

Intra-articular steroid injection for knee osteoarthritis in non diabetics and controlled diabetics.

Assessment of the functional outcome of intra-articular steroid injection for knee osteoarthritis in non diabetics and controlled diabetics - An observational study. - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/08/071790
Enrollment
86
Registered
2024-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: NIL: This is an observational study Control Intervention1: triamcinolone acetonide 40 mg: functional outcome following intra articular steroid in non diabetic and controlled diabetic Co

Sponsors

All India Institute of Medical Sciences (AIIMS), Guwahati
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals (non-diabetics and controlled diabetics) 45 years of age or older with unilateral or bilateral symptomatic knee pain (NRS =4/10) on most days for the past more than 1 month and radiologically (X-ray) confirmed knee OA with Kellgren-Lawrence (KL) radiographic severity grade 2–3

Exclusion criteria

Exclusion criteria: Refusal to consent. Patients (with or without diabetes) having HbA1c = 7% at baseline IASI in the past 3 months History of any systemic inflammatory arthritis History of trauma, surgery or infection in the affected knee joint Overlying skin and soft tissue infection Uncontrolled bleeding diathesis Known case of cancer Clinically significant cognitive impairment Known allergy to triamcinolone acetonide or lignocaine

Design outcomes

Primary

MeasureTime frame
To determine the responsiveness of intra articular steroid injections in knee osteoarthritic patients.Timepoint: baseline and at 2 weeks and 4 weeks.—

Secondary

MeasureTime frame
Observe CRP levels in each groupTimepoint: At 2 weeks and 4 weeks;Observe local or systemic complicationsTimepoint: At 2 weeks and 4 weeks;Quantify dose of rescue analgesicTimepoint: At 2 weeks and 4 weeks—

Countries

India

Contacts

Public ContactDr Sristi Kumari

All India Institute of Medical Sciences, Guwahati

ankurchintus@gmail.com7042929671

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026